Awakn Life Sciences Past Earnings Performance
Past criteria checks 0/6
Awakn Life Sciences has been growing earnings at an average annual rate of 38.3%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 44.1% per year.
Key information
38.3%
Earnings growth rate
49.4%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -44.1% |
| Return on equity | n/a |
| Net Margin | -4,543.9% |
| Last Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Awakn Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 24 | 0 | -3 | 2 | 1 |
| 31 Jul 24 | 0 | -3 | 2 | 1 |
| 30 Apr 24 | 0 | -4 | 3 | 1 |
| 31 Jan 24 | 0 | -4 | 3 | 1 |
| 31 Oct 23 | 0 | -3 | 4 | 1 |
| 31 Jul 23 | 0 | -3 | 4 | 1 |
| 30 Apr 23 | 0 | -3 | 3 | 1 |
| 31 Jan 23 | 0 | -5 | 4 | 1 |
| 31 Oct 22 | 0 | -8 | 5 | 3 |
| 31 Jul 22 | 0 | -10 | 6 | 3 |
| 30 Apr 22 | 0 | -18 | 7 | 4 |
| 31 Jan 22 | 0 | -16 | 6 | 3 |
| 31 Oct 21 | 0 | -13 | 4 | 2 |
Quality Earnings: AWKN is currently unprofitable.
Growing Profit Margin: AWKN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AWKN is unprofitable, but has reduced losses over the past 5 years at a rate of 38.3% per year.
Accelerating Growth: Unable to compare AWKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWKN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: AWKN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:38 |
| End of Day Share Price | 2024/12/13 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Awakn Life Sciences Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Andrew Partheniou | Stifel Canada |